



STANDARDELE MINIMALE, NECESARE ȘI OBLIGATORII
PENTRU ÎNSCRIERE LA EXAMENUL DE PROMOVARE
pentru titlul didactic de **Conferențiar universitar**

Domeniile Medicină și Farmacie

- Deținerea diplomei de Doctor în domeniul postului¹
***Diplomă de doctor**, Seria J, Nr. 0014861, acordată de Universitatea de Medicină și Farmacie “Grigore T. Popa” Iași în domeniul FARMACIE, D-nei Pânzariu V. Andreea-Teodora, ca urmare a susținerii tezei de doctorat intitulată: Sinteza și evaluarea biologică a unor noi derivați de alfa-aminoacizi”, Conducător de doctorat: Prof. Univ. Dr. Lenuța Profire, în baza Ordinului Ministerului Educației și Cercetării Științifice nr. 5954 din 7.12.2015.*
- Deținerea titlului de medic/farmacist primar la disciplinele de concurs cu corespondent în Rețeaua Sanitară, în specialitatea postului¹. În cazul specialităților înființate în ultimii 5 ani, candidatul pentru funcția de conferențiar va face dovada deținerii titlului de medic specialist în specialitatea postului și a titlului de medic primar într-o alta specialitate conexă sau mai largă.
.....**NU SE APLICĂ**.....
- Dovada că desfășoară activitatea profesională didactică cu studenții, în specialitatea corespunzătoare disciplinei postului didactic scos la concurs, într-o secție/clinică în care se desfășoară activități de învățământ cu studenții și rezidenții și cu care Universitatea are contract de colaborare (pentru posturile din domeniul Medicină, specialitățile clinice, care au corespondent în rețeaua Ministerului Sănătății)
.....**NU SE APLICĂ**.....

¹ Nume diplomă, serie, număr



RECTORAT

+40 232 211 818 tel / +40 232 211 820 fax

rectorat@umfiasi.ro



WORLD FEDERATION FOR
MEDICAL EDUCATION

eua

EUROPEAN
UNIVERSITY
ASSOCIATION

- 6 articole ISI² autor principal, publicate în reviste din domeniul postului pentru care candidează (medicină, medicină dentară, farmacie), dintre care 5 de la ultima promovare

12 articole (originale/review) autor principal*, dintre care 7 de la ultima promovare (febr. 2020)

1. Caluian I, **Iacob A-T***, Sava A, Apotrosoaei M, Profire L. Design and in Silico Evaluation of Novel Tacrine-Ferulic Acid Derivatives. Farmacia 2025. 73 (5): 1246-1255 (F.I.=1.3) [DESIGN AND IN SILICO EVALUATION OF NOVEL TACRINE-FERULIC ACID DERIVATIVES – Farmacia Journal](#)
[LINK DOSAR](#)
2. **Iacob AT***, Ababei-Bobu A, Chirliu O-M, Lupascu F-G, Vasincu I-M, Apotrosoaei M, Profire B-S, Tauser G-R, Lupascu D, Profire L. A state-of-the-art review on recent biomedical application of polysaccharide-based niosomes as drug delivery systems. Polymers 2025, 17, 1566 (F.I.=4.9). <https://doi.org/10.3390/polym17111566>
[LINK DOSAR](#)
3. **Iacob AT***, Lupascu FG, Profire BS, Apotrosoaei M, Vasincu I-M, Ionescu OM, Lupascu D, Tauser RG, Profire L. Evaluation of anti-inflammatory activity of nitro-L-arginine methyl ester derivatives with thiazolidin-4-one scaffold. Med. Surg. J. – Rev. Med. Chir.2024, 128 (4):908-914. (F.I.=0.2).[EVALUATION OF ANTI-INFLAMMATORY ACTIVITY OF NITRO-L-ARGININE METHYL ESTER DERIVATIVES WITH THIAZOLIDIN-4-ONE SCAFFOLD](#)
[LINK DOSAR](#)
4. Turcov D, Barna S, Profire L, **Iacob A-T***, Lisă G, Puițel A-C, Zbranca A, Șuteu D. Physico-chemical characterization of the antioxidant mixture resveratrol-ferulic acid for applications in dermato-cosmetic products, FARMACIA, 2022, Vol. 70, 3, 410-416. (F.I.=1.6) https://farmaciajournal.com/wp-content/uploads/art-05-Turcov_Barna_Profire_410-416.pdf
[LINK DOSAR](#)
5. Dragostin I, Dragostin O-M, **Iacob A-T***, Dragan M, Chitescu CL, Confederat L, Zamfir A-S, Tatia R, Stan CD, Zamfir CL. Chitosan Microparticles Loaded with New Non-Cytotoxic Isoniazid Derivatives for the Treatment of Tuberculosis: in vitro and in vivo studies. Polymers 2022, 14, 2310. (F.I.=5.0) <https://doi.org/10.3390/polym14122310>
[LINK DOSAR](#)
6. Ionescu OM, **Iacob A-T***, Mignon A, Van Vlierberghe S, Baican M, Danu M, Ibănescu C, Simionescu N, Profire L. Design, preparation and in vitro characterization of biomimetic and bioactive chitosan/polyethylene oxide based nanofibers as wound dressings. International Journal of Biological Macromolecules 2021, 193, 996-1008. (F.I.= 8.025) <https://doi.org/10.1016/j.ijbiomac.2021.10.166> WOS- 000729556400002
[LINK DOSAR](#)
7. **Iacob A-T***, Lupașcu FG, Apotrosoaei M, Vasincu IM, Tauser RG, Lupașcu D. Giusca SE, Caruntu I-D. Recent Biomedical Approaches for Chitosan Based Materials as Drug Delivery Nanocarrier. Pharmaceutics 2021, 13(4), 587. (F.I= 6.525) <https://www.mdpi.com/1999-4923/13/4/587>
[LINK DOSAR](#)
8. **Iacob A-T***, Drăgan M, Ionescu OM, Profire L, Ficai A, Andronescu E, Confederat LG, Lupașcu D. An Overview of Biopolymeric Electrospun Nanofibers Based on Polysaccharides for Wound Healing Management. Pharmaceutics 2020, 12, 983 (F.I= 6.321); <https://doi.org/10.3390/pharmaceutics12100983>
[LINK DOSAR](#)
9. Drăgan M, Dragostin O, **Iacob A-T***, Profire L, Stan CD, Tuchiluş C. Antioxidant and antimicrobial potential of new azetidin-2-one of ferulic acid. Farmacia 2019, 67 (5): 789-793. (F.I.=1.607) <https://doi.org/10.31925/farmacia.2019.5.6> 2019-05-art-06-Dragan Stan Tuchilus 789-793.pdf
[LINK DOSAR](#)

² Autori, titlu articol, nume revistă, volum, număr, paginație, factor de impact al revistei pentru anul publicării articolului, link

10. **Iacob A-T***, Drăgan M, Ghețu N, Pieptu D, Vasile C, Buron F, Routier S, Giusca SE, Caruntu ID, Profire L. Preparation, characterization and wound healing effects of new membranes based on chitosan, hyaluronic acid and arginine derivatives. Polymers 2018, 10 (6): 607 article number (F.I.=3.164) <https://doi.org/10.3390/polym10060607>
LINK DOSAR
11. **Pânzariu AT***, Apotrosoaei M, Vasincu IM, Drăgan M, Constantin S, Buron F, Routier S, Profire L, Tuchilus C. Synthesis and biological evaluation of new 1,3-thiazolidine-4-one derivatives of nitro-L-arginine methyl ester. Chemistry Central Journal 2016, 10(6): 1-14 (F.I. = 2.442) <https://bmcchem.biomedcentral.com/articles/10.1186/s13065-016-0151-6>
LINK DOSAR
12. **Pânzariu A***, Vasincu I, Dragostin OM, Drăgan M, Buron F, Routier S, Profire L. New arginine derivatives - synthesis and biological evaluation. Farmacia 2015, 63 (4): 581-585. ISI (F.I.=1.162). [2015-04-art-19-Panzariu Profire 581-585.pdf](https://doi.org/10.1016/j.farm.2015.04.019)
LINK DOSAR

- 3 articole ISI² co-autor, publicate în reviste din domeniul postului pentru care candidează (medicină, medicină dentară, farmacie), dintre care 2 de la ultima promovare

23 articole (originale/review) co-autor, dintre care de la ultima promovare (febr. 2020)

1. Tauser RG, Vasincu IM, **Iacob A-T**, Apotrosoaei M, Profire B-S, Lupascu FG, Chirliu OM, Profire L. A State of the art Overview On (Epi)Genomics And Personalised Skin Rejuvenating Strategies. Pharmaceutics 2025, 17 (12): 1585. (F.I.=5.5). [A State-of-the-Art Overview on \(Epi\)Genomics and Personalized Skin Rejuvenating Strategies](https://doi.org/10.3390/pharmaceutics17121585)
<https://doi.org/10.3390/pharmaceutics17121585>
LINK DOSAR
2. Ababei-Bobu A, Profire BS, **Iacob A-T**, Chirliu O-M, Lupașcu F-G, Profire L. Niosomes as Vesicular Carriers: From Formulation Strategies to Stimuli-Responsive Innovative Modulations for Targeted Drug Delivery. Pharmaceutics 2025 17(11), 1473; (F.I.=5.5). <https://doi.org/10.3390/pharmaceutics17111473>
LINK DOSAR
3. Vasincu IM, Apotrosoaei M, **Iacob AT**, Lupașcu FG, Focșă A, Chirliu O-M, Lupașcu D, Taușer R-G, Profire L. Evaluation of neurologic effects of some new ibuprofen thiazolidin-4-one derivatives. Med. Surg. J. –Rev. Med. Chir. Iași 2025, 129(2):480-487; (F.I.=0.2). doi: 10.22551/MSJ.2025.02.20 [EVALUATION OF NEUROLOGIC EFFECTS OF SOME NEW IBUPROFEN THIAZOLIDIN-4-ONE DERIVATIVES | The Medical-Surgical Journal](https://doi.org/10.22551/MSJ.2025.02.20)
LINK DOSAR
4. Tauser RG, Lupascu F-G, Profire B-S, **Iacob A-T**, Vasincu I.-M., Apotrosoaei M., Chirliu O-M, Lupascu D, Profire L. Aptamer-Nanoconjugates as Potential Theranostics in Major Neuro-Oncological and Neurodegenerative Disorders. Pharmaceutics 2025, 17 (9):1106, (F.I.=5.5). <https://doi.org/10.3390/pharmaceutics17091106>
LINK DOSAR
5. Lupașcu FG, Sava A, Tătărușanu SM, **Iacob AT**, Dascalu A, Profire BS, Vasincu IM, Apotrosoaei M, Gîsca TC, Turin-Moleavin IA, Profire L. New Chitosan-Based Co-Delivery Nanosystem for Diabetes Mellitus Therapy. Polymers 2024, 16 (13): 1825 (F.I.=4.9). <https://www.mdpi.com/2073-4360/16/13/1825>
LINK DOSAR
6. Vasincu IM, Apotrosoaei M, Lupascu F, **Iacob AT**, Giusca SE, Caruntu ID, Marangoci NL, Petrovici AR, Stanciu GD, Tamba BI, Profire BS, Focsa A-V, Pinteala M and Profire L. Complexes of Ibuprofen Thiazolidin-4-One Derivatives with β -Cyclodextrin: Characterization and In Vivo Release Profile and Biological Evaluation. Pharmaceutics 2023, 15, 2492. (FI=4.9) <https://doi.org/10.3390/pharmaceutics15102492>
LINK DOSAR

7. Tatarusanu S-M, Lupascu F-M, Profire B-S, Szilaghy A, Gardikiotis I, **Iacob A-T**, Caluian I, Herciu L, Gîscă T-C, Baican MC, Crivoi F, Profire L. Modern Approaches in Wounds Management. Polymers 2023, 15, 3648. (F.I.=4.7) <https://doi.org/10.3390/polym15173648>
[LINK DOSAR](#)
8. Focşa A, Apotrosoaei M, **Iacob A-T**, Vasincu I-M, Drăgan M, Sava A, Bîrsan M, Petrovici A-R, Stan C-D, Profire L. New metal complexes with aril-acetic structure: preparation, characterization, and in vitro antiinflammatory effects. FARMACIA, 2023, Vol. 71, 3, 491-500 pp. (F.I.=1.6)
[NEW METAL COMPLEXES WITH ARIL-ACETIC STRUCTURE: PREPARATION, CHARACTERIZATION, AND IN VITRO ANTIINFLAMMATORY EFFECTS - Farmacia Journal art-06-Focsa Stan Profire 491-500.pdf](#)
[LINK DOSAR](#)
9. Tatarusanu SM, Sava AI, Profire B-S, Pinteala T, Jitareanu A, **Iacob A-T**, Lupascu F, Simionescu N, Rosca I, Profire L. New Smart Bioactive and Biomimetic Chitosan-Based Hydrogels for Wounds Care Management. Pharmaceutics 2023, 15, 975. (F.I.=4.9) [New Smart Bioactive and Biomimetic Chitosan-Based Hydrogels for Wounds Care Management](#)
[LINK DOSAR](#)
10. Lupaşcu F, Constantin SM, Profire BS, Vasincu I, Ionescu OM, **Iacob AT**, Iurascu T, Ababei A, Apotrosoaei M, Jităreanu A, Sava A, Profire L. Design and optimization method for obtaining pioglitazone and curcumin-loaded chitosan Nanoparticles. Med. Surg. J. – Rev. Med. Chir. 2022, 126(1): 126-134, (FI=0.1).
<https://www.revmedchir.ro/index.php/revmedchir/article/view/2543>
[LINK DOSAR](#)
11. Ionescu OM, Profire BS, **Iacob AT**, Lupaşcu F, Lupaşcu D, Tauşer R-G, Iurascu T, Ababei A, Apotrosoaei M, Jităreanu A, Sava A, Profire L. Design and optimization method for obtaining new chitosan-based nanofibers for wound healing application. Med. Surg. J. – Rev. Med. Chir. 2022, 126(1): 118-125. doi: 10.22551/MSJ.2022.01.15 (FI=0.1).
<https://www.revmedchir.ro/index.php/revmedchir/article/view/2542>
[LINK DOSAR](#)
12. Ionescu OM, Mignon A, **Iacob AT**, Simionescu N, Confederat LG, Tuchilus C, Profire L. New Hyaluronic Acid/Polyethylene Oxide-based electrospun nanofibers: design, characterization and In Vitro biological evaluation. Polymers 2021, 13, 129 (F.I.=4.967)
<https://www.mdpi.com/2073-4360/13/8/1291>
[LINK DOSAR](#)
13. Drăgan M, Stan CD, **Iacob AT**, Dragostin OM, Boanca M, Lupusoru CE, Zamfir CL, Profire L. Biological evaluation of azetidine-2-one derivatives of ferulic acid as potent anti-inflammatory agents. Processes 2020; 8, 1401. (F.I.=2.847) <https://www.mdpi.com/2227-9717/8/11/1401>
[LINK DOSAR](#)
14. Focşa A, **Iacob A**, Vasincu I, Constantin S, Andriescu L, Sava A, Buron F, Routier S, Profire L. The antioxidant potential evaluation of diclofenac derivatives with hydrazones structure. Farmacia, 2020, 68 (2): 329 -334. (F.I. =1.433)
<https://doi.org/10.31925/farmacia.2020.2.19> [THE RELATIONSHIP BETWEEN VACCINATION AND THE DEVELOPMENT OF AUTOIMMUNE DISEASES](#)
[LINK DOSAR](#)
15. Apotrosoaei M, Vasincu IM, Constantin SM, **Iacob A-T**, Tauşer GR, Lupaşcu D, Lupuşoru C-E, Profire L. The effects of new 1,3-thiazolidine-4-ones with pyrazolone scaffold on motor function in mice. Farmacia 2019, 67 (2): 305-310 (F.I. =1.607).
<https://doi.org/10.31925/farmacia.2019.2.15> [2019-02-art-15-Apotrosoaei Vasincu Profire 305-310.pdf](#)
[LINK DOSAR](#)
16. Lupaşcu D, Tuchiluş C, Lupaşcu F, Constantin S, Apotrosoaei M, Vasincu IM, **Iacob AT**, Profire L. Rutin semisynthetic derivatives with antifungal properties. Farmacia 2017, 65(2): 184-188. (F.I. =1.507) [2017-02-art-04-Dan Lupascu Profire 184-188.pdf](#)
[LINK DOSAR](#)

17. Drăgan M, Stan CD, **Iacob A**, Profire L. Assessment of *in vitro* antioxidant and antiinflammatory activities of new azetidin-2-one derivatives of ferulic acid. Farmacia 2016, 64(5): 717-721. (F.I.=1.348) [2016-05-art-11-Stan Catalina 717-721.pdf](#)
[LINK DOSAR](#)
18. Constantin S, Buron F, Routier S, Confederat L, **Iacob A-T**, Miron A, Profire L. Studies on xanthine derivatives (II). Synthesis and antioxidant effects of some hydrazones with xanthine structure. Farmacia 2016, 64(4): 565-571 (F.I.=1.348). [2016-04-art-14-Constantin Profire 565-571.pdf](#)
[LINK DOSAR](#)
19. Drăgan M, Stan CD, **Pânzariu A**, Profire L. Evaluation of anti-inflammatory potential of some new ferulic acid derivatives. Farmacia 2016, 64(2): 194-197 (F.I.=1.348). [2016-02-art-06-Stan Catalina 194-197.pdf](#)
[LINK DOSAR](#)
20. Dragostin OM, Samal SK, Dash M, Lupascu F, **Pânzariu A**, Tuchilus C, Ghetu N, Danciu M, Dubrue P, Pieptu D, Vasile C, Tatia R, Profire L. New antimicrobial chitosan derivatives for wound dressing applications. Carbohydrate Polymers 2016, 141: 28-40 (F.I.=4.811). <https://doi.org/10.1016/j.carbpol.2015.12.078>
[LINK DOSAR](#)
21. Dragostin OM, Samal SK, Lupascu F, **Pânzariu A**, Dubrue P, Lupascu D, Tuchilus C, Vasile C, Profire L. Development and Characterization of Novel Films Based on Sulfonamide-Chitosan Derivatives for Potential Wound Dressing. International Journal of Molecular Sciences 2015, 16(12): 29843-29855 (F.I. = 3.257). <https://doi.org/10.3390/ijms161226204>
[LINK DOSAR](#)
22. Drăgan MW, Stan CD, **Pânzariu A**, Jităreanu A, Profire L. New thiazolidine-4-ones of ferulic acid with antioxidant potential. Farmacia 2015, 63(1): 150-154. ISI (F.I. = 1.162). [art-24-Dragan Porfire 150-154](#)
[LINK DOSAR](#)
23. Vasincu IM, Apotrosoaei M, **Pânzariu A-T**, Buron F, Routier S, Profire L. The synthesis and the Biological Evaluation of New 1,3-thiazolidine-4-one Derivatives of 2-(4- isobutylphenyl) propionic Acid. Molecules 2014, 19(9): 15005-15025. (F.I.=2.416). [Synthesis and Biological Evaluation of New 1,3-Thiazolidine-4-one Derivatives of 2-\(4-Isobutylphenyl\)propionic Acid](#).
[LINK DOSAR](#)

- H-Index- 4

.....**H-index 13** utilizând ISI Web of Science, Core Collection

[LINK DOSAR](#)

Web of Science™ Smart Search Research Assistant

Andreea-Teodora Iacob

Researcher Search Author Records Author Profile Author Profile Author Profile

Andreea-Teodora Iacob (Iacob, Andreea-Teodora) | Grigore T. Popa University of Medicine and Pharmacy Iasi

Identifiers Web of Science ResearcherID: AAS-5361-2021

Published names Panzariu, Andreea Iacob, Andreea Teodora Iacob, Andreea Teodora Iacob, Andreea Show more

Subject Categories General & Internal Medicine; Pharmacology & Pharmacy; Polymer Science; Chemistry; Biochemistry & Molecular Biology

Metrics Open dashboard

Profile summary

46	Total documents
45	Publications indexed in Web of Science
45	Web of Science Core Collection publications
1	Preprint
0	Dissertations or Theses
0	Non-indexed publications
22	Verified peer reviews
0	Verified editor records
0	Awarded grants

Web of Science Core Collection metrics

13	45
H-Index	Publications
788	727
Sum of Times Cited	Citing Articles
748	705
Sum of Times Cited without self-citations	Citing Articles without self-citations
1	1

Documents Peer Review

All Indexed Documents (46) Web of Science Core Collection (45) Preprints (1)

Filters Select Filters Author Position All Publications Sort by Date: newest first 1 of 1

45 results Manage

- Factor cumulat de impact (autor principal) - 6

.....**FCIAP=42,246**.....

LINK DOSAR

*Notă asupra metodei de calcul (pentru domeniul **Farmacie**):*

1. *Va fi luat în considerare Indexul Hirsch calculat utilizând ISI Web of Science, Core Collection, Clarivate Analytics, pentru întreaga carieră a candidatului ("all years")*
 2. *O revistă cotate ISI este o revistă pentru care Clarivate Analytics calculează și publică factorul de impact în "Journal Citation Reports"*
 3. *Autorul sau autorii principali ai unei publicații se consideră a fi oricare dintre următorii:*
 - a) *Primul autor*
 - b) *Autorul corespondent*
 - c) *Alți autori, a căror contribuție este indicată explicit în cadrul publicației a fi egală cu contribuția primului autor sau a autorului corespondent*
 - d) *Ultimul autor*
 4. *Factorul cumulat de impact va fi calculat pentru articolele la care candidatul este autor principal (FCIAP)*
- FCIAP – suma factorilor de impact ai articolelor publicate de autor în calitate de autor principal în reviste cotate ISI.*
5. *În analiză vor fi incluse articole originale și reviews. În cazuri speciale, privind alte tipuri de publicații, posibile, dar probabil cu o contribuție mică în evaluare, decizia va aparține comisiei de evaluare.*

Nu sunt luate în considerare adevărurile de accept de publicare.